Back to today’s briefing

Story perspectives

Study Links GLP-1 Drugs to Blindness Risks in Diabetes

6/8/2025

45 5

Summary

Story summary

A groundbreaking study from the University of Toronto uncovers a troubling link: diabetes patients on GLP-1 drugs, such as semaglutide, face double the risk of neovascular age-related macular degeneration (nAMD). The European Medicines Agency has issued a stark warning that these medications could also trigger non-arteritic anterior ischemic optic neuropathy (NAION), potentially resulting in permanent blindness.

1 of 1

Story summary

A groundbreaking study from the University of Toronto uncovers a troubling link: diabetes patients on GLP-1 drugs, such as semaglutide, face double the risk of neovascular age-related macular degeneration (nAMD). The European Medicines Agency has issued a stark warning that these medications could also trigger non-arteritic anterior ischemic optic neuropathy (NAION), potentially resulting in permanent blindness.